Miriam Bujny

Chief Development Officer (CDO) at Sapreme Technologies BV

Miriam joined Sapreme as CDO in 2020. She is an experienced translational science lead with background in RNA and antibody therapeutics, and uses this background at Sapreme to drive the development of next-generation macromolecules that circumvent endosomal entrapment. Over the last ten years, Miriam has held leadership positions in various drug discovery and clinical development roles. As head of the Translational Science department and Senior Director R&D at ProQR Therapeutics, she recently led early development activities for ProQR’s RNA therapy programs.

From 2012 to 2016, she worked in various roles for Janssen, including anti-viral antibody therapy development. From 2010 to 2012, Miriam worked at Crucell, before its acquisition by Johnson & Johnson, in the Innovation & Discovery Labs on antibody discovery and engineering. Miriam holds a Ph.D. in biochemistry from the University of Bristol with a specialization in endosomal transport. She completed postdoctoral training in the lab of Dr. Xiaowei Zhuang at Harvard University.


Title: Antibody-targeted cytoplasmic delivery of fusion proteins and antibody fragments using Sapreme’s endosomal escape enhancers